Benznidazole - Chemo group

Drug Profile

Benznidazole - Chemo group

Latest Information Update: 16 Jun 2016

Price : $50

At a glance

  • Originator Chemo Group
  • Developer Chemo Group; Drugs for Neglected Diseases Initiative Foundation; Mundo Sano
  • Class Antiprotozoals
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Chagas disease

Most Recent Events

  • 08 Jun 2016 Clinical trials in Chagas' disease in USA (unspecified route)
  • 08 Jun 2016 Chemo group, Drugs for Neglected Diseases initiative and Mundo Sano enter into a collaboration agreement to register benznidazole for the treatment of Chagas' disease in USA, Mexico, Columbia and countries in Latin America
  • 08 Jun 2016 Chemo group intends to file for Priority review voucher for benznidazole with the US FDA for the treatment of Chagas' disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top